These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 3277542)

  • 41. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982.
    Lever WF; Schaumburg-Lever G
    Arch Dermatol; 1984 Jan; 120(1):44-7. PubMed ID: 6691714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasmapheresis as a supplementary treatment in pemphigus.
    Błaszczyk M; Chorzelski T; Daszyński J; Gaczkowski A; Jabłońska S; Beutner EH
    Arch Immunol Ther Exp (Warsz); 1981; 29(6):763-7. PubMed ID: 7349095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pemphigus: associations and management guidelines: facts and controversies.
    Ruocco E; Wolf R; Ruocco V; Brunetti G; Romano F; Lo Schiavo A
    Clin Dermatol; 2013; 31(4):382-390. PubMed ID: 23806155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method.
    Ogata K; Yasuda K; Matsushita M; Kodama H
    J Dermatol; 1999 Apr; 26(4):236-9. PubMed ID: 10343469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)].
    Benoit Corven C; Carvalho P; Prost C; Verret JL; Saiag P; Noblesse I; Bedane C; Chosidow O; Young P; Roujeau JC; Joly P
    Ann Dermatol Venereol; 2003 Jan; 130(1 Pt 1):13-5. PubMed ID: 12605150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris.
    Fellner MJ; Katz JM; McCabe JB
    Arch Dermatol; 1978 Jun; 114(6):889-94. PubMed ID: 666324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
    Aoyama Y; Nagasawa C; Nagai M; Kitajima Y
    Eur J Dermatol; 2008; 18(5):557-60. PubMed ID: 18693160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N; Qureshi A; Ruocco E; Ahmed AR
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pemphigus vulgaris: a review of treatment over a 19-year period.
    Ljubojević S; Lipozencić J; Brenner S; Budimcić D
    J Eur Acad Dermatol Venereol; 2002 Nov; 16(6):599-603. PubMed ID: 12482043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Invasive cutaneous aspergillosis complicating immunosuppressive therapy for recalcitrant pemphigus vulgaris.
    Thakur BK; Bernardi DM; Murali MR; McClain SA; Clark RA
    J Am Acad Dermatol; 1998 Mar; 38(3):488-90. PubMed ID: 9520034
    [No Abstract]   [Full Text] [Related]  

  • 51. Diagnosis and treatment of pemphigus.
    Tsuruta D; Ishii N; Hashimoto T
    Immunotherapy; 2012 Jul; 4(7):735-45. PubMed ID: 22853759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A patient with immunological features of paraneoplastic pemphigus in the absence of a detectable malignancy.
    Verrini A; Cannata G; Cozzani E; Terracini M; Parodi A; Rebora A
    Acta Derm Venereol; 2002; 82(5):382-4. PubMed ID: 12430743
    [No Abstract]   [Full Text] [Related]  

  • 53. Childhood pemphigus.
    Wananukul S; Pongprasit P
    Int J Dermatol; 1999 Jan; 38(1):29-35. PubMed ID: 10065607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of cyclophosphamide in azathioprine failures in pemphigus.
    Ahmed AR; Hombal S
    J Am Acad Dermatol; 1987 Sep; 17(3):437-42. PubMed ID: 3655023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
    Mahajan VK; Sharma NL; Sharma RC; Garg G
    Int J Dermatol; 2005 Oct; 44(10):821-7. PubMed ID: 16207182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases.
    Mignogna MD; Lo Muzio L; Mignogna RE; Carbone R; Ruoppo E; Bucci E
    J Oral Pathol Med; 2000 Apr; 29(4):145-52. PubMed ID: 10766391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Plasmapheresis in the treatment of bullous skin diseases].
    Błaszcyk M; Chorzelski T; Daszyński J; Klenowska Z; Beutner EH; Jabłońska S
    Przegl Dermatol; 1979; 66(4):399-404. PubMed ID: 493563
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.
    Kasperkiewicz M; Shimanovich I; Meier M; Schumacher N; Westermann L; Kramer J; Zillikens D; Schmidt E
    Br J Dermatol; 2012 Jan; 166(1):154-60. PubMed ID: 21910700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pemphigus vulgaris in three adolescents: the course of the disease.
    Popadic S; Medenica L; Skiljevic D; Djakovic Z; Nikolic M
    Australas J Dermatol; 2011 Aug; 52(3):e3-7. PubMed ID: 21834807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.